Tenax Therapeutics Reports $15.8 Million Net Loss in Latest Quarter, Increases Focus on Levosimendan

Tenax Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $15.8 million for the quarter, compared to a loss of $4.0 million in the same period last year, marking an increase of 299%. For the nine months ended September 30, 2025, the net loss was $37.1 million, up from $11.3 million in the prior year, reflecting a 227% increase. Total operating expenses for the third quarter reached $16.8 million, a substantial rise from $4.6 million in the previous year, driven primarily by increased research and development costs associated with ongoing clinical trials.

In terms of financial position, Tenax reported total current assets of $102.8 million as of September 30, 2025, an increase from $96.7 million at the end of 2024. The company’s cash and cash equivalents also rose to $99.4 million, up from $94.9 million at the end of the previous fiscal year. However, total liabilities remained stable at $6.6 million, unchanged from the previous period. The increase in cash reserves is attributed to successful capital raises, including a $25 million private placement in March 2025, which is intended to fund the ongoing Phase 3 LEVEL clinical trial for levosimendan.

Operationally, Tenax is focused on advancing its clinical programs, particularly the LEVEL trial, which evaluates levosimendan for treating pulmonary hypertension. The company has deprioritized a Phase 3 trial for imatinib, redirecting resources to the ongoing studies of levosimendan. As of the end of September 2025, Tenax had enrolled 230 patients in the LEVEL trial, with plans to expand its global footprint through a second Phase 3 study, LEVEL-2, expected to commence later this year.

The company has also seen a significant increase in its workforce, which has contributed to higher salary and benefits expenses. Research and development costs surged by 232% in the third quarter compared to the previous year, primarily due to expenses related to clinical trial activities. General and administrative expenses also rose sharply, reflecting increased legal and professional fees as well as stock-based compensation costs. The company anticipates continued operational losses as it progresses through its clinical development phases, with expectations of needing additional capital to support its initiatives.

Looking ahead, Tenax Therapeutics remains optimistic about its financial outlook, believing it has sufficient resources to fund operations through at least 2027. The company plans to continue its focus on developing levosimendan and potentially imatinib, while also exploring additional product candidates. However, it acknowledges the inherent risks and uncertainties associated with clinical trials and the need for substantial capital to achieve its long-term goals.